MedDataX Logo

Expanded Access to Upadacitinib

NCT ID: NCT04159597

Last Updated: 2025-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Expanded Access to Risankizumab

NCT03914261

Crohn's Disease Ulcerative Colitis (UC)
NO_LONGER_AVAILABLE

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

NCT05930275

Crohn's Disease
ACTIVE_NOT_RECRUITING

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

NCT03345849

Crohn's Disease
COMPLETED PHASE3

Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

NCT05496348

Ulcerative Colitis
RECRUITING

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823

Crohn's Disease
ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease Ulcerative Colitis Idiopathic Arthritis (Including sJIA, pJIA, or JPsA) Atopic Dermatitis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Upadacitinib

Upadacitinib will be administered as oral solution.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-494 Rinvoq C25-267

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- The participant must not be eligible for upadacitinib clinical trial.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ABBVIE CALL CENTER

Role: CONTACT

[email protected]
844-663-3742

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C25-267

Identifier Type: OTHER

Identifier Source: secondary_id

C20-082

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
NCT03345836 COMPLETED PHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068 ACTIVE_NOT_RECRUITING PHASE3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
NCT02365649 COMPLETED PHASE2
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
NCT06581042 RECRUITING
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
NCT07073079 RECRUITING
Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
NCT06856135 AVAILABLE
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
NCT00338650 COMPLETED PHASE3
A Study of Abatacept in Patients With Active Crohn's Disease
NCT00406653 TERMINATED PHASE3
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
NCT06023030 RECRUITING
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00055523 COMPLETED PHASE2
A Study of Abatacept in Patients With Active Ulcerative Colitis
NCT00410410 COMPLETED PHASE3
An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease
NCT03362736 NO_LONGER_AVAILABLE
Fluorescence Imaging of IBD and RA Using Adalimumab-800CW
NCT03938701 RECRUITING PHASE2
Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
NCT02738125 COMPLETED
Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease
NCT07258641 NOT_YET_RECRUITING PHASE1/PHASE2
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
NCT01861249 TERMINATED PHASE2
Remission in Subjects With Crohn's Disease, 1 Year Phase
NCT00055497 COMPLETED PHASE3
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
NCT02782663 COMPLETED PHASE2
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
NCT02148718 COMPLETED PHASE4
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
NCT02451839 COMPLETED
Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
NCT01494857 UNKNOWN PHASE3
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT02819635 COMPLETED PHASE2/PHASE3
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
NCT03606499 COMPLETED
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
NCT00427921 COMPLETED PHASE3
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
NCT01659138 TERMINATED PHASE2